Skip to content
★ Sign in to follow
Upstream Bio, Inc. logo

Upstream Bio, Inc. Stock: price and insider trades · United States

US·Mcap US$152.4MHealth Care

No insider purchase over the last 90 days. The latest, by ORBIMED ADVISORS LLC, was filed 17 Oct 2024.

Insider Decl.
29
Thresholds
n/a
Buy Volume
€31M
3 ops. · all time
Sell Volume
€71,864
12 ops. · all time

Upstream Bio, Inc.: what insiders have been doing

Upstream Bio, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 16 November 2026, 17 filings were filed, from 5 insiders.

Only sales appear on the open market, 12 sales in all totalling €72k, filed by 5 insiders. Sutherland Everett Rand filed the largest sale, €17k, on 17 March 2026.

Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Across the 3,183 companies tracked on its exchange, the median is 24 filings; at 17 filings, this issuer sits below that mark. Looking back to 2024, when coverage begins, insiders filed 3 purchases and 12 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 2.9 m USD and net income at -143.4 m USD.

In the same sector, recent insider purchases at Dynavox Group AB and Drägerwerk AG & Co. KGaA also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Who traded when

BuySale
Aaron Deykin3 sales
Allison Ambrose3 sales
Adam Houghton2 sales
Everett Rand Sutherland2 sales
Michael Gray2 sales

Since the insiders bought

  • Filed 17 Oct 2024 · 761 days ago · €10.3M
    -10.9%
    Entry US$25.88 · Close at T+365 US$23.05
  • Filed 17 Oct 2024 · 761 days ago · €18.4M
    -10.9%
    Entry US$25.88 · Close at T+365 US$23.05

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Upstream Bio, Inc. Buy (bullish), based on 5 analysts. Average price target: US$21.40.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

US$2.78
Analyst consensus
5 analysts
Buy
US$9.00Target US$21.40(+670%)US$40.00
Income statement
RevenueUS$2.9M
EBITDA-US$160.2M-5612% margin
Net income-US$143.4M-5026.0% margin
Valuation
PER (forward)-1.1x
P/Book0.7x
Beta1.61
Balance sheet & cash
Market capUS$152.4M
Total debtUS$1.3M
Free Cash Flow-US$133.4M
Debt / Equity0%
Profitability & ownership
ROE-53.5%
ROA-34.4%
% insiders15.1%
% institutions92.8%
Last declaration on 17 September 2026

T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.

Declarations29 total
  • ▼
    General CounselExecutives
    2,663 USD40SEC
    485 shares@ US$5.490.0017% mcap26.6% of flowCommon StockSEC:0001193125-26-394318:0
  • ▼
    Chief Medical OfficerExecutives
    4,914 USD40SEC
    895 shares@ US$5.490.0032% mcap26.3% of flowCommon StockSEC:0001193125-26-394330:0
  • ▼
    CFO and COOExecutives
    4,683 USD49SEC
    853 shares@ US$5.490.0030% mcap37.0% of flowCommon StockSEC:0001193125-26-394322:0
  • ▼
    Chief Business OfficerExecutives
    3,843 USD41SEC
    700 shares@ US$5.490.0025% mcap37.0% of flowCommon StockSEC:0001193125-26-394324:0
  • ▼
    Chief Executive OfficerExecutives
    11,502 USD53SEC
    2,095 shares@ US$5.490.0074% mcap37.0% of flowCommon StockSEC:0001193125-26-394325:0
  • ▼
    General CounselExecutives
    2,910 USD26SEC
    477 shares@ US$6.1028.9% of flowCommon StockSEC:0001193125-26-274119:0
  • ▼
    Chief Medical OfficerExecutives
    5,460 USD26SEC
    895 shares@ US$6.1029.0% of flowCommon StockSEC:0001193125-26-274121:0
  • ▼
    CFO and COOExecutives
    7,915 USD43SEC
    852 shares@ US$9.2963.0% of flowCommon StockSEC:0001193125-26-111138:0
  • ▼
    Chief Business OfficerExecutives
    6,494 USD35SEC
    699 shares@ US$9.2963.0% of flowCommon StockSEC:0001193125-26-111105:0
  • ▼
    Chief Medical OfficerExecutives
    8,305 USD35SEC
    894 shares@ US$9.2963.0% of flowCommon StockSEC:0001193125-26-111134:0
  • ▼
    Chief Executive OfficerExecutives
    19,444 USD46SEC
    2,093 shares@ US$9.2963.0% of flowCommon StockSEC:0001193125-26-111124:0
  • ▼
    General CounselExecutives
    4,413 USD35SEC
    475 shares@ US$9.2962.6% of flowCommon StockSEC:0001193125-26-111121:0
  • ◆
    Chief Medical OfficerExecutives
    0SEC
    32,000 shares0Common StockSEC:0001193125-26-004757:0
  • ◆
    Chief Business OfficerExecutives
    0SEC
    25,000 shares0Common StockSEC:0001193125-26-004755:0
  • ◆
    General CounselExecutives
    0SEC
    17,000 shares0Common StockSEC:0001193125-26-004756:0
  • ◆
    CFO and COOExecutives
    0SEC
    30,500 shares0Common StockSEC:0001193125-26-004758:0
  • ◆
    Chief Executive OfficerExecutives
    0SEC
    75,000 shares0Common StockSEC:0001193125-26-004754:0
  • ▲
    DirectorExecutives

    Same trade as the filing by Orbimed Advisors LLC, counted once

    11M USD34SEC
    660,000 shares@ US$17.0080.0% of flowCommon StockSEC:0000947871-24-000807:3
    Canonical exit: 13 Jan 2025 (T+90)
  • ▲
    DirectorExecutives

    Same trade as the filing by Orbimed Advisors LLC, counted once

    3M USD28SEC
    165,000 shares@ US$17.0020.0% of flowCommon StockSEC:0000947871-24-000807:1
    Canonical exit: 13 Jan 2025 (T+90)
  • ●
    Related company / holdingExecutives
    0SEC
    2,887,833 sharesCommon StockSEC:0000947871-24-000806:2
  • ●
    Related company / holdingExecutives
    0SEC
    3,147,000 sharesCommon StockSEC:0000950170-24-115295:1
  • ●
    Related company / holdingExecutives
    0SEC
    1,172,410 sharesCommon StockSEC:0000950170-24-115295:2
  • ●
    DirectorExecutives
    0SEC
    2,887,833 sharesCommon StockSEC:0000947871-24-000807:2
  • ▲
    Related company / holdingExecutives
    11M USD34SEC
    660,000 shares@ US$17.0080.0% of flowCommon StockSEC:0000947871-24-000806:3
    Canonical exit: 13 Jan 2025 (T+90)
  • ▲
    Related company / holdingExecutives
    3M USD28SEC
    165,000 shares@ US$17.0020.0% of flowCommon StockSEC:0000947871-24-000806:1
    Canonical exit: 13 Jan 2025 (T+90)

25 of 29 declarations

About Upstream Bio, Inc.

Upstream Bio, Inc. is a company listed on the XNAS market, focused on developing innovative biological therapies. It aims to provide solutions for immunological and inflammatory diseases.

Written on 25 June 2026 from the filings and market data available that day. Live figures are in the blocks above.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations

The weekly insider digest, free

One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.